诺和诺德回应“司美回流药”:支持并全力配合打击非法行为 继续推进授权认证渠道体系

格隆汇
Sep 22
就司美格鲁肽“回流药”问题,诺和诺德中国今日表示,针对近期相关报道,公司始终将患者安全置于首位,一贯坚决支持并全力配合国家有关部门依法对医保回流药等非法行为进行严厉打击,以维护国家医保基金安全和患者合法权益。在声明中,诺和诺德表示,将继续携手医疗机构、零售药房及电商平台等产业链合作伙伴,共同支持规范用药管理和患者教育,持续推进授权认证渠道体系(包括品牌直供及官方授权渠道),协同提升药品流通全链路质量管理和追溯能力,为患者提供来源清晰、储运合规、可追溯的药品及专业服务。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10